Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6992)
All Articles published online
|
Publishing Process of This Article
|
Nov 21, 2014 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Ohyama T, Sato K, Yamazaki Y, Hashizume H, Horiguchi N, Kakizaki S, Mori M, Kusano M, Yamada M. MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i43/16227.htm |
| Number | Citing Articles |
| 1 |
A. L. João, F. Reis, R. Fernandes. The incretin system ABCs in obesity and diabetes – novel therapeutic strategies for weight loss and beyond. Obesity Reviews 2016; 17(7): 553 doi: 10.1111/obr.12421
|
| 2 |
Anna Veelen, Edmundo Erazo-Tapia, Jan Oscarsson, Patrick Schrauwen. Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?. Molecular Metabolism 2021; 46: 101158 doi: 10.1016/j.molmet.2020.101158
|
| 3 |
Rashmi Pathak, Avinash Kumar, Henry A. Palfrey, Kirsten P. Stone, Narayan R. Raju, Thomas W. Gettys, Subramanyam N. Murthy. Prolonged effects of DPP-4 inhibitors on steato-hepatitic changes in Sprague–Dawley rats fed a high-cholesterol diet. Inflammation Research 2022; 71(5-6): 711 doi: 10.1007/s00011-022-01572-4
|
| 4 |
Seung Hee Choi, Jaechan Leem, Sungmi Park, Chong-Kee Lee, Keun-Gyu Park, In-Kyu Lee. Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice. Canadian Journal of Physiology and Pharmacology 2017; 95(2): 129 doi: 10.1139/cjpp-2016-0026
|
| 5 |
D Dutta, S Kalra, M Sharma. Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy. Journal of Postgraduate Medicine 2017; 63(2): 114 doi: 10.4103/0022-3859.191007
|
| 6 |
Amalia Gastaldelli, Kenneth Cusi. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Reports 2019; 1(4): 312 doi: 10.1016/j.jhepr.2019.07.002
|
| 7 |
Zi Long, Meng Cao, Shuhao Su, Guangyuan Wu, Fansen Meng, Hao Wu, Jiangzheng Liu, Weihua Yu, Kamran Atabai, Xin Wang. Inhibition of hepatocyte nuclear factor 1b induces hepatic steatosis through DPP4/NOX1-mediated regulation of superoxide. Free Radical Biology and Medicine 2017; 113: 71 doi: 10.1016/j.freeradbiomed.2017.09.016
|
| 8 |
María José Ojeda‐Montes, Aleix Gimeno, Sarah Tomas‐Hernández, Adrià Cereto‐Massagué, Raúl Beltrán‐Debón, Cristina Valls, Miquel Mulero, Gerard Pujadas, Santiago Garcia‐Vallvé. Activity and selectivity cliffs for DPP‐IV inhibitors: Lessons we can learn from SAR studies and their application to virtual screening. Medicinal Research Reviews 2018; 38(6): 1874 doi: 10.1002/med.21499
|
| 9 |
Wataru Yano, Noriyuki Inoue, Shiori Ito, Takahiro Itou, Misako Yasumura, Yasunobu Yoshinaka, Sumihiko Hagita, Moritaka Goto, Takashi Nakagawa, Keisuke Inoue, Sohei Tanabe, Kohei Kaku. Mechanism of lipid‐lowering action of the dipeptidyl peptidase‐4 inhibitor, anagliptin, in low‐density lipoprotein receptor‐deficient mice. Journal of Diabetes Investigation 2017; 8(2): 155 doi: 10.1111/jdi.12593
|
| 10 |
Tolulope Eniola Omolekulo, Olugbenga Samuel Michael, Lawrence Aderemi Olatunji. Sodium acetate improves disrupted glucoregulation and hepatic triglyceride content in insulin-resistant female rats: involvement of adenosine deaminase and dipeptidyl peptidase-4 activities. Naunyn-Schmiedeberg's Archives of Pharmacology 2019; 392(1): 103 doi: 10.1007/s00210-018-1569-2
|
| 11 |
Yumei Ye, Mandeep Bajaj, Hsiu-Chiung Yang, Jose R. Perez-Polo, Yochai Birnbaum. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovascular Drugs and Therapy 2017; 31(2): 119 doi: 10.1007/s10557-017-6725-2
|
| 12 |
Mi-Kyung Kim, Yu Na Chae, Gook-Jun Ahn, Chang Yell Shin, Song-hyen Choi, Eun Kyoung Yang, Yong Sung Sohn, Moon-Ho Son. Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models. Archives of Pharmacal Research 2017; 40(2): 268 doi: 10.1007/s12272-016-0864-z
|
| 13 |
Weijia Xie, Xiaoxiao Song, Zhenjie Liu. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases. Vascular Pharmacology 2018; 109: 17 doi: 10.1016/j.vph.2018.05.010
|
| 14 |
Xiaoqing Ma, Wenhua Du, Shanshan Shao, Chunxiao Yu, Lingyan Zhou, Fei Jing. Vildagliptin Can Alleviate Endoplasmic Reticulum Stress in the Liver Induced by a High Fat Diet. BioMed Research International 2018; 2018: 1 doi: 10.1155/2018/5045182
|
| 15 |
Asuka Morita, Eri Mukai, Ayano Hiratsuka, Tomozumi Takatani, Toshihiko Iwanaga, Eun Young Lee, Takashi Miki. Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function. Endocrine 2016; 51(3): 429 doi: 10.1007/s12020-015-0733-4
|
| 16 |
Lana Kosi‐Trebotic, Anita Thomas, Jürgen Harreiter, Marek Chmelik, Siegfried Trattnig, Alexandra Kautzky‐Willer. Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients. European Journal of Clinical Investigation 2017; 47(11): 829 doi: 10.1111/eci.12817
|
| 17 |
Jin Hyun Kim, Si Jung Jang, Gu Seob Roh, Hyun Seop Cho, Heeyoung Kang, Soo Kyoung Kim. Protective Effects of Evogliptin on Steatohepatitis in High-Fat-Fed Mice. International Journal of Molecular Sciences 2020; 21(18): 6743 doi: 10.3390/ijms21186743
|
| 18 |
Minyoung Lee, Eugene Shin, Jaehyun Bae, Yongin Cho, Ji-Yeon Lee, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-75288-y
|
| 19 |
Natalie Chaves Cayuela, Gabrielly Pascoa Negreti, Roberto Rasslan, Marcia Kiyomi Koike, Edna Frasson de Souza Montero. Oxidative stress on ischemia/reperfusion injury in mice with non-alcoholic hepatic steatosis or steatohepatitis. Acta Cirurgica Brasileira 2018; 33(9): 753 doi: 10.1590/s0102-865020180090000003
|
| 20 |
Anna Licata, Giuseppina T. Russo, Annalisa Giandalia, Marcella Cammilleri, Clelia Asero, Irene Cacciola. Impact of Sex and Gender on Clinical Management of Patients with Advanced Chronic Liver Disease and Type 2 Diabetes. Journal of Personalized Medicine 2023; 13(3): 558 doi: 10.3390/jpm13030558
|
| 21 |
Eun Ju Bae. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control. Archives of Pharmacal Research 2016; 39(8): 1114 doi: 10.1007/s12272-016-0813-x
|
| 22 |
Tae-Hyoung Kim, Jeong-Ha Lee, Yu Na Chae, Il-Hoon Jung, Mi-Kyung Kim. Additive effects of evogliptin in combination with pioglitazone on fasting glucose control through direct and indirect hepatic effects in diabetic mice. European Journal of Pharmacology 2018; 830: 95 doi: 10.1016/j.ejphar.2018.04.033
|
| 23 |
Waihong Chung, Kittichai Promrat, Jack Wands. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. World Journal of Hepatology 2020; 12(9): 533-557 doi: 10.4254/wjh.v12.i9.533
|